FDA Lifts Hold on Phase 3 Trial Testing Venclexta in Myeloma Patients with Common Genetic Abnormality
The U.S. Food and Drug Administration (FDA) has lifted its hold on the CANOVA Phase 3 clinical trial, which is evaluating the experimental therapeutic Vencexta (venetoclax) plus dexamethasone in people with relapsed or refractory multiple myeloma who test positive for a common genetic abnormality. Venclexta (sold as Venclyxto…